{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:21:24Z","timestamp":1791084084401,"version":"4.1.0"},"reference-count":308,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1124\/pharmrev.123.000815","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T13:10:16Z","timestamp":1694437816000},"page":"49-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin"],"prefix":"10.1016","volume":"76","author":[{"given":"Anagha","family":"Gogate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordyn","family":"Belcourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia Zongxun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Kolmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Chalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajith","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarush","family":"Kolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherouk M.","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-9271","authenticated-orcid":false,"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Bahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore P.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 E.","family":"Manautou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6537-5415","authenticated-orcid":false,"given":"Xiao-bo","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pharmrev.123.000815_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","article-title":"RNAi therapeutics: principles, prospects and challenges","volume":"59","author":"Aagaard","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/pharmrev.123.000815_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","article-title":"Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1124\/pharmrev.123.000815_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1124\/pharmrev.123.000815_bib5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/psp4.12969","article-title":"A population pharmacokinetic and pharmacokinetic-pharmacodynamic analysis of vupanorsen from phase I and phase II studies","volume":"12","author":"Ahn","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/pharmrev.123.000815_bib6","article-title":"Acquired Hemophilia A Post-COVID-19 Vaccination: A Case Report and Review","volume":"14","author":"Al Hennawi","year":"2022","journal-title":"Cureus"},{"key":"10.1124\/pharmrev.123.000815_bib7","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort","year":"2019","journal-title":"Blood Transfus"},{"key":"10.1124\/pharmrev.123.000815_bib8","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1124\/pharmrev.123.000815_bib9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.123.000815_bib10","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.3390\/pharmaceutics14112389","article-title":"Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology","volume":"14","author":"Amanat","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1124\/pharmrev.123.000815_bib11","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.1093\/nar\/gkab718","article-title":"Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides","volume":"49","author":"Anderson","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/pharmrev.123.000815_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2019.07.002","article-title":"Acute hepatic porphyrias: Current diagnosis & management","volume":"128","author":"Anderson","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1124\/pharmrev.123.000815_bib13","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3324\/haematol.2018.209619","article-title":"Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds","volume":"104","author":"Andersson","year":"2019","journal-title":"Haematologica"},{"key":"10.1124\/pharmrev.123.000815_bib14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3109\/15412555.2014.974746","article-title":"Alpha-1 Antitrypsin Deficiency-Associated Chronic Obstructive Pulmonary Disease: A Family Perspective","volume":"12","author":"Anzueto","year":"2015","journal-title":"COPD"},{"key":"10.1124\/pharmrev.123.000815_bib15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.chest.2021.09.041","article-title":"Prevalence of Alpha-1 Antitrypsin Deficiency, Self-Reported Behavior Change, and Health Care Engagement Among Direct-to-Consumer Recipients of a Personalized Genetic Risk Report","volume":"161","author":"Ashenhurst","year":"2022","journal-title":"Chest"},{"key":"10.1124\/pharmrev.123.000815_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/jpet.121.000805","article-title":"Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine-Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans","volume":"379","author":"Ayyar","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.123.000815_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40262-020-00940-9","article-title":"Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria","volume":"60","author":"Badri","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pharmrev.123.000815_bib18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cells9010137","article-title":"RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs","volume":"9","author":"Bajan","year":"2020","journal-title":"Cells"},{"key":"10.1124\/pharmrev.123.000815_bib19","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib20","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/hep.29313","article-title":"Acute hepatic porphyrias: Recommendations for evaluation and long-term management","volume":"66","author":"Balwani","year":"2017","journal-title":"Hepatology"},{"key":"10.1124\/pharmrev.123.000815_bib21","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/JU.0000000000001528","article-title":"Mutations in HOGA1 do Not Confer a Dominant Phenotype Manifesting as Kidney Stone Disease","volume":"205","author":"Bar","year":"2021","journal-title":"J Urol"},{"key":"10.1124\/pharmrev.123.000815_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12890-021-01466-x","article-title":"Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro\/con debate on a working hypothesis","volume":"21","author":"Barjaktarevic","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1124\/pharmrev.123.000815_bib23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.25122\/jml-2022-0103","article-title":"Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A","volume":"15","author":"Batorova","year":"2022","journal-title":"J Med Life"},{"key":"10.1124\/pharmrev.123.000815_bib24","doi-asserted-by":"crossref","first-page":"9237","DOI":"10.1073\/pnas.161293498","article-title":"Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition","volume":"98","author":"Bauer","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.123.000815_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney Int"},{"key":"10.1124\/pharmrev.123.000815_bib27","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.3390\/ijms19113426","article-title":"Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease","volume":"19","author":"Benito-Vicente","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1124\/pharmrev.123.000815_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/nmt-2018-0037","article-title":"Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis","volume":"9","author":"Benson","year":"2019","journal-title":"Neurodegener Dis Manag"},{"key":"10.1124\/pharmrev.123.000815_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib30","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"10.1124\/pharmrev.123.000815_bib31","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.123.000815_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5527\/wjn.v4.i2.235","article-title":"Primary and secondary hyperoxaluria: Understanding the enigma","volume":"4","author":"Bhasin","year":"2015","journal-title":"World J Nephrol"},{"key":"10.1124\/pharmrev.123.000815_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14218\/JCTH.2014.00039","article-title":"Acute Hepatic Porphyria","volume":"3","author":"Bissell","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"10.1124\/pharmrev.123.000815_bib34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/13696998.2020.1724118","article-title":"Real-world annualized healthcare utilization and expenditures among insured US patients with acute intermittent porphyria (AIP) treated with hemin","volume":"23","author":"Blaylock","year":"2020","journal-title":"J Med Econ"},{"key":"10.1124\/pharmrev.123.000815_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ymgme.2019.03.002","article-title":"Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs)","volume":"128","author":"Bonkovsky","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1124\/pharmrev.123.000815_bib36","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.amjmed.2014.06.036","article-title":"Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium","volume":"127","author":"Bonkovsky","year":"2014","journal-title":"Am J Med"},{"key":"10.1124\/pharmrev.123.000815_bib37","first-page":"172","article-title":"Alpha-1 Antitrypsin Deficiency-Mediated Liver Toxicity: Why Do Some Patients Do Poorly? What Do We Know So Far?","volume":"7","author":"Bouchecareilh","year":"2020","journal-title":"Chronic Obstr Pulm Dis"},{"key":"10.1124\/pharmrev.123.000815_bib38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/mp.55.2.127","article-title":"Haemophilia A and haemophilia B: molecular insights","volume":"55","author":"Bowen","year":"2002","journal-title":"Mol Pathol"},{"issue":"Suppl I","key":"10.1124\/pharmrev.123.000815_bib39","doi-asserted-by":"crossref","first-page":"I131","DOI":"10.1093\/eurheartjsupp\/suac104","article-title":"The treatment of amyloidosis is being refined","volume":"24","author":"Cantone","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"10.1124\/pharmrev.123.000815_bib40","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/lt.23744","article-title":"Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency\u2013related cirrhosis","volume":"19","author":"Carey","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1124\/pharmrev.123.000815_bib41","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia A and B: molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"key":"10.1124\/pharmrev.123.000815_bib42","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1038\/ncomms6853","article-title":"DNase II-dependent DNA digestion is required for DNA sensing by TLR9","volume":"6","author":"Chan","year":"2015","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.123.000815_bib43","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/humu.23067","article-title":"Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease","volume":"37","author":"Chen","year":"2016","journal-title":"Hum Mutat"},{"key":"10.1124\/pharmrev.123.000815_bib44","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1038\/s41598-019-42523-0","article-title":"Systematic evaluation of 2\u2032-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.123.000815_bib45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41525-021-00176-x","article-title":"Rare versus common diseases: a false dichotomy in precision medicine","volume":"6","author":"Chung","year":"2021","journal-title":"NPJ Genom Med"},{"issue":"Suppl 8","key":"10.1124\/pharmrev.123.000815_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ndt\/10.supp8.3","article-title":"Epidemiology of primary hyperoxaluria type 1. Soci\u00e9t\u00e9 de N\u00e9phrologie and the Soci\u00e9t\u00e9 de N\u00e9phrologie P\u00e9diatrique","volume":"10","author":"Cochat","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/pharmrev.123.000815_bib47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13023-020-01399-4","article-title":"A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"15","author":"Coelho","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1124\/pharmrev.123.000815_bib48","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib49","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","article-title":"Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy","volume":"10","author":"Coelho","year":"2021","journal-title":"Neurol Ther"},{"key":"10.1124\/pharmrev.123.000815_bib50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ajt.16732","article-title":"Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: Incidence, risk factors, and effect on renal allograft function","volume":"22","author":"Cornell","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1124\/pharmrev.123.000815_bib51","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/humu.9200","article-title":"Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2","volume":"22","author":"Cregeen","year":"2003","journal-title":"Hum Mutat"},{"key":"10.1124\/pharmrev.123.000815_bib52","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1124\/dmd.122.001008","article-title":"Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research","volume":"51","author":"Cronin","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.123.000815_bib53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.123.000815_bib54","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/mt.2016.136","article-title":"Integrated Safety Assessment of 2\u2032-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers","volume":"24","author":"Crooke","year":"2016","journal-title":"Mol Ther"},{"key":"10.1124\/pharmrev.123.000815_bib55","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/nat.2016.0650","article-title":"The Effects of 2\u2032-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/pharmrev.123.000815_bib56","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2125.2012.04469.x","article-title":"Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B","volume":"76","author":"Crooke","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.123.000815_bib57","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1124\/pharmrev.123.000815_bib58","doi-asserted-by":"crossref","first-page":"16259","DOI":"10.1021\/acsomega.1c01755","article-title":"Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation","volume":"6","author":"Cui","year":"2021","journal-title":"ACS Omega"},{"key":"10.1124\/pharmrev.123.000815_bib59","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/IJNRD.S293682","article-title":"Lumasiran in the Management of Patients with Primary Hyperoxaluria Type 1: From Bench to Bedside","volume":"15","author":"D\u2019Ambrosio","year":"2022","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1124\/pharmrev.123.000815_bib60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1124\/pharmrev.123.000815_bib61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular Mechanisms and Biological Functions of siRNA","volume":"13","author":"Dana","year":"2017","journal-title":"Int J Biomed Sci"},{"key":"10.1124\/pharmrev.123.000815_bib62","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s13760-023-02188-z","article-title":"A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium","volume":"123","author":"De Bleecker","year":"2023","journal-title":"Acta Neurol Belg"},{"key":"10.1124\/pharmrev.123.000815_bib63","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1289\/ehp.6511","article-title":"Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed","volume":"111","author":"de Serres","year":"2003","journal-title":"Environ Health Perspect"},{"key":"10.1124\/pharmrev.123.000815_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.715523","article-title":"Acute Hepatic Porphyria: Pathophysiological Basis of Neuromuscular Manifestations","volume":"15","author":"de Souza","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1124\/pharmrev.123.000815_bib65","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol Ther"},{"key":"10.1124\/pharmrev.123.000815_bib66","series-title":"Box Warning","author":"Delong","year":"2023"},{"key":"10.1124\/pharmrev.123.000815_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269749","article-title":"Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates","volume":"17","author":"Devalaraja-Narashimha","year":"2022","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.123.000815_bib68","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J Clin Med"},{"key":"10.1124\/pharmrev.123.000815_bib69","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1111\/bcp.15468","article-title":"Population pharmacokinetic\/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis","volume":"88","author":"Diep","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.123.000815_bib70","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.semnephrol.2004.01.003","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy","volume":"24","author":"Dillon","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1124\/pharmrev.123.000815_bib71","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00277-021-04715-5","article-title":"The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey","volume":"101","author":"Dingli","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1124\/pharmrev.123.000815_bib72","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1634\/theoncologist.2008-0086","article-title":"FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"13","author":"Dmytrijuk","year":"2008","journal-title":"Oncologist"},{"key":"10.1124\/pharmrev.123.000815_bib73","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/oli.2005.15.105","article-title":"Induction of toll-like receptors and NALP\/PAN\/PYPAF family members by modified oligonucleotides in lung epithelial carcinoma cells","volume":"15","author":"Drygin","year":"2005","journal-title":"Oligonucleotides"},{"key":"10.1124\/pharmrev.123.000815_bib74","first-page":"113","article-title":"RNA interference: silencing in the cytoplasm and nucleus","volume":"5","author":"Dudley","year":"2003","journal-title":"Curr Opin Mol Ther"},{"key":"10.1124\/pharmrev.123.000815_bib75","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jacl.2016.04.013","article-title":"Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia","volume":"10","author":"Duell","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1124\/pharmrev.123.000815_bib76","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2147\/COPD.S130440","article-title":"Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review","volume":"12","author":"Edgar","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1124\/pharmrev.123.000815_bib77","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bpg.2013.08.002","article-title":"Mechanisms of liver involvement in systemic disease","volume":"27","author":"Edwards","year":"2013","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1124\/pharmrev.123.000815_bib78","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ihj.2019.03.004","article-title":"Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction","volume":"71","author":"Enas","year":"2019","journal-title":"Indian Heart J"},{"key":"10.1124\/pharmrev.123.000815_bib79","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"10.1124\/pharmrev.123.000815_bib80","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/MNH.0000000000000229","article-title":"Oxalate, inflammasome, and progression of kidney disease","volume":"25","author":"Ermer","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1124\/pharmrev.123.000815_bib81","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000381738","article-title":"The Genetics of IgA Nephropathy: An Overview from Western Countries","volume":"1","author":"Feehally","year":"2015","journal-title":"Kidney Dis"},{"key":"10.1124\/pharmrev.123.000815_bib82","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1124\/pharmrev.123.000815_bib83","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib84","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000560","article-title":"Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers","volume":"3","author":"Flaim","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1124\/pharmrev.123.000815_bib85","first-page":"33","article-title":"Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency","volume":"12","author":"Foil","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1124\/pharmrev.123.000815_bib86","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol Pathol"},{"key":"10.1124\/pharmrev.123.000815_bib87","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: State-of-the-Art and Future Perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"key":"10.1124\/pharmrev.123.000815_bib88","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2215\/CJN.14730920","article-title":"Phase 1\/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial","volume":"16","author":"Frishberg","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.123.000815_bib89","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.3390\/jcm11226773","article-title":"Recent Advances in Gene Therapy for Familial Hypercholesterolemia: An Update Review","volume":"11","author":"Fu","year":"2022","journal-title":"J Clin Med"},{"key":"10.1124\/pharmrev.123.000815_bib90","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/15476286.2022.2052641","article-title":"Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications","volume":"19","author":"Gangopadhyay","year":"2022","journal-title":"RNA Biol"},{"key":"10.1124\/pharmrev.123.000815_bib91","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nbt1216-1213","article-title":"Alnylam terminates revusiran program, stock plunges","volume":"34","author":"Garber","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1124\/pharmrev.123.000815_bib92","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.3390\/jcm11133884","article-title":"Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias","volume":"11","author":"Gareri","year":"2022","journal-title":"J Clin Med"},{"key":"10.1124\/pharmrev.123.000815_bib93","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib94","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nri3713","article-title":"Assembly and localization of Toll-like receptor signalling complexes","volume":"14","author":"Gay","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/pharmrev.123.000815_bib95","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00240-023-01453-3","article-title":"Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)","volume":"51","author":"Goldfarb","year":"2023","journal-title":"Urolithiasis"},{"key":"10.1124\/pharmrev.123.000815_bib96","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/hep.30936","article-title":"EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks","volume":"71","author":"Gouya","year":"2020","journal-title":"Hepatology"},{"key":"10.1124\/pharmrev.123.000815_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100336","article-title":"Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: A 2019 update","volume":"10","author":"Gu","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"10.1124\/pharmrev.123.000815_bib98","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/pharmrev.123.000815_bib99","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40265-013-0042-2","article-title":"Mipomersen sodium: first global approval","volume":"73","author":"Hair","year":"2013","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.123.000815_bib100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10545-010-9237-9","article-title":"Harderoporphyria due to homozygosity for coproporphyrinogen oxidase missense mutation H327R","volume":"34","author":"Hasanoglu","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"10.1124\/pharmrev.123.000815_bib101","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med"},{"key":"10.1124\/pharmrev.123.000815_bib102","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00467-022-05684-1","article-title":"Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial","volume":"38","author":"Hayes","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1124\/pharmrev.123.000815_bib103","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pharmrev.123.000815_bib104","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCRESAHA.115.307611","article-title":"Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease","volume":"118","author":"Herrington","year":"2016","journal-title":"Circ Res"},{"key":"10.1124\/pharmrev.123.000815_bib105","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s40265-022-01735-x","article-title":"Improving Treatment Options for Primary Hyperoxaluria","volume":"82","author":"Hoppe","year":"2022","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.123.000815_bib106","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: First Global Approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.123.000815_bib107","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s40265-021-01560-8","article-title":"Pegcetacoplan: First Approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.123.000815_bib108","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2215\/CJN.06820613","article-title":"Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.123.000815_bib109","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1124\/pharmrev.123.000815_bib110","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1124\/pharmrev.123.000815_bib111","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1086\/511444","article-title":"ALAD porphyria is a conformational disease","volume":"80","author":"Jaffe","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1124\/pharmrev.123.000815_bib112","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2019-125867","article-title":"Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US","volume":"134","author":"Jalbert","year":"2019","journal-title":"Blood"},{"key":"10.1124\/pharmrev.123.000815_bib113","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0192623318792537","article-title":"The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies","volume":"46","author":"Janas","year":"2018","journal-title":"Toxicol Pathol"},{"key":"10.1124\/pharmrev.123.000815_bib114","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0897190016683304","article-title":"Praluent (Alirocumab)-Induced Renal Injury","volume":"30","author":"Jhaveri","year":"2017","journal-title":"J Pharm Pract"},{"key":"10.1124\/pharmrev.123.000815_bib115","series-title":"Inotersen","author":"Joubran","year":"2022"},{"key":"10.1124\/pharmrev.123.000815_bib116","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1124\/pharmrev.123.000815_bib117","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1124\/pharmrev.123.000815_bib118","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/mus.27675","article-title":"Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial","volume":"66","author":"Karam","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1124\/pharmrev.123.000815_bib119","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2021.03.036","article-title":"Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen","volume":"324","author":"Karwatowska-Prokopczuk","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1124\/pharmrev.123.000815_bib120","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacl.2022.06.005","article-title":"Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia","volume":"16","author":"Karwatowska-Prokopczuk","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1124\/pharmrev.123.000815_bib121","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: First Global Approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.123.000815_bib122","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: First Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.123.000815_bib123","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.3390\/jcm10194501","article-title":"Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment","volume":"10","author":"Knoppova","year":"2021","journal-title":"J Clin Med"},{"key":"10.1124\/pharmrev.123.000815_bib124","article-title":"Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials","author":"Koenig","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1124\/pharmrev.123.000815_bib125","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/ndt\/10.12.2224","article-title":"Changing pattern of primary hyperoxaluria in Switzerland","volume":"10","author":"Kopp","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/pharmrev.123.000815_bib126","series-title":"Acute Hepatic Porphyria","author":"Kothadia","year":"2022"},{"key":"10.1124\/pharmrev.123.000815_bib127","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1681\/ASN.2014121223","article-title":"Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria","volume":"26","author":"Krieger","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.123.000815_bib128","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221091046","article-title":"The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria","volume":"13","author":"Kulasekararaj","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1124\/pharmrev.123.000815_bib129","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"10.1124\/pharmrev.123.000815_bib130","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1365-2516.2009.02074.x","article-title":"Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention\u2019s (CDC) Universal Data Collection (UDC) project","volume":"15","author":"Kulkarni","year":"2009","journal-title":"Haemophilia"},{"key":"10.1124\/pharmrev.123.000815_bib131","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1039\/D2CS00788F","article-title":"Targeted delivery of oligonucleotides using multivalent protein-carbohydrate interactions","volume":"52","author":"Kumar","year":"2023","journal-title":"Chem Soc Rev"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.123.000815_bib132","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000481636","article-title":"Immunoglobulin A Nephropathy: Advances in Understanding of Pathogenesis and Treatment","volume":"47","author":"Lafayette","year":"2018","journal-title":"Am J Nephrol"},{"key":"10.1124\/pharmrev.123.000815_bib133","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/637850","article-title":"Comparison between the repression potency of siRNA targeting the coding region and the 3\u2032-untranslated region of mRNA","volume":"2013","author":"Lai","year":"2013","journal-title":"BioMed Res Int"},{"key":"10.1124\/pharmrev.123.000815_bib134","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: First Approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.123.000815_bib135","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2516.2007.01458.x","article-title":"Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B","volume":"13","author":"Lambert","year":"2007","journal-title":"Haemophilia"},{"key":"10.1124\/pharmrev.123.000815_bib136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231892","article-title":"Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5","volume":"15","author":"Latuszek","year":"2020","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.123.000815_bib137","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14779072.2021.1955348","article-title":"Volanesorsen for treatment of familial chylomicronemia syndrome","volume":"19","author":"Lazarte","year":"2021","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1124\/pharmrev.123.000815_bib138","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/2047487319869400","article-title":"Lifestyle factors and high-risk atherosclerosis: Pathways and mechanisms beyond traditional risk factors","volume":"27","author":"Lechner","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1124\/pharmrev.123.000815_bib139","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"10.1124\/pharmrev.123.000815_bib140","first-page":"483","article-title":"The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice","volume":"8","author":"Lepor","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1124\/pharmrev.123.000815_bib141","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-12-800148-6.00004-3","article-title":"Lipid Nanoparticles for Short Interfering RNA Delivery","volume":"88","author":"Leung","year":"2014","journal-title":"Adv Genet"},{"key":"10.1124\/pharmrev.123.000815_bib142","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/dmd.117.078741","article-title":"Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells","volume":"46","author":"Li","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.123.000815_bib143","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/nmt-2020-0020","article-title":"Experience of patisiran with transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis","volume":"10","author":"Lin","year":"2020","journal-title":"Neurodegener Dis Manag"},{"key":"10.1124\/pharmrev.123.000815_bib144","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1573396314666181113094517","article-title":"Alpha1-Antitrypsin Deficiency: Transition of Care for the Child With AAT Deficiency into Adulthood","volume":"15","author":"Lin","year":"2019","journal-title":"Curr Pediatr Rev"},{"key":"10.1124\/pharmrev.123.000815_bib145","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41577-021-00577-0","article-title":"Regulation of the nucleic acid-sensing Toll-like receptors","volume":"22","author":"Lind","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/pharmrev.123.000815_bib146","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/acsptsci.2c00110","article-title":"Nedosiran, a Candidate siRNA Drug for the Treatment of Primary Hyperoxaluria: Design, Development, and Clinical Studies","volume":"5","author":"Liu","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1124\/pharmrev.123.000815_bib147","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1039\/C5CS00911A","article-title":"Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view","volume":"45","author":"Lu","year":"2016","journal-title":"Chem Soc Rev"},{"key":"10.1124\/pharmrev.123.000815_bib148","doi-asserted-by":"crossref","first-page":"a122","DOI":"10.1210\/jendso\/bvaa122","article-title":"Management of Familial Hypercholesterolemia: Current Status and Future Perspectives","volume":"5","author":"Lui","year":"2020","journal-title":"J Endocr Soc"},{"key":"10.1124\/pharmrev.123.000815_bib149","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S219979","article-title":"Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care","volume":"16","author":"Luigetti","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1124\/pharmrev.123.000815_bib150","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/ki.2015.252","article-title":"New developments in the genetics, pathogenesis, and therapy of IgA nephropathy","volume":"88","author":"Magistroni","year":"2015","journal-title":"Kidney Int"},{"key":"10.1124\/pharmrev.123.000815_bib151","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.genom.1.1.507","article-title":"Apolipoprotein E: far more than a lipid transport protein","volume":"1","author":"Mahley","year":"2000","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1124\/pharmrev.123.000815_bib152","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2147\/DDDT.S281631","article-title":"Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy","volume":"16","author":"Majeed","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/pharmrev.123.000815_bib153","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2147\/DDDT.S162913","article-title":"Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis","volume":"13","author":"Mathew","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/pharmrev.123.000815_bib154","first-page":"232","article-title":"Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular Dystrophy","volume":"4","author":"Matsuo","year":"2021","journal-title":"Japan Med Assoc J"},{"key":"10.1124\/pharmrev.123.000815_bib156","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia","volume":"8","author":"McGowan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1124\/pharmrev.123.000815_bib157","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/MOL.0000000000000793","article-title":"Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations","volume":"32","author":"McIntosh","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"10.1124\/pharmrev.123.000815_bib158","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40265-019-01068-2","article-title":"Ravulizumab: First Global Approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.123.000815_bib159","article-title":"HOGA1 Gene Mutations of Primary Hyperoxaluria Type 3 in Tunisian Patients","volume":"31","author":"M\u2019dimegh","year":"2017","journal-title":"J Clin Lab Anal"},{"key":"10.1124\/pharmrev.123.000815_bib160","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fimmu.2017.00331","article-title":"RNA interference-induced innate immunity, off-target effect, or immune adjuvant?","volume":"8","author":"Meng","year":"2017","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.123.000815_bib161","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","article-title":"Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial","volume":"81","author":"Michael","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/pharmrev.123.000815_bib162","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.tips.2022.02.003","article-title":"siRNA drug Leqvio (inclisiran) to lower cholesterol","volume":"43","author":"Migliorati","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/pharmrev.123.000815_bib163","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1124\/dmd.121.000417","article-title":"Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs","volume":"50","author":"Migliorati","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.123.000815_bib164","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/hae.14403","article-title":"Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States","volume":"27","author":"Miller","year":"2021","journal-title":"Haemophilia"},{"key":"10.1124\/pharmrev.123.000815_bib165","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40139-017-0147-5","article-title":"Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions","volume":"5","author":"Mitchell","year":"2017","journal-title":"Curr Pathobiol Rep"},{"key":"10.1124\/pharmrev.123.000815_bib166","doi-asserted-by":"crossref","first-page":"F409","DOI":"10.1152\/ajprenal.00373.2018","article-title":"Dietary oxalate and kidney stone formation","volume":"316","author":"Mitchell","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/pharmrev.123.000815_bib167","series-title":"Ala Dehydratase Deficiency Porphyria","author":"Mohan","year":"2022"},{"key":"10.1124\/pharmrev.123.000815_bib168","doi-asserted-by":"crossref","first-page":"551","DOI":"10.15171\/apb.2018.064","article-title":"Potential of Peptide Nucleic Acids in Future Therapeutic Applications","volume":"8","author":"Montazersaheb","year":"2018","journal-title":"Adv Pharm Bull"},{"key":"10.1124\/pharmrev.123.000815_bib169","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3109\/0886022X.2013.866512","article-title":"Statins stabilize the renal function of IgA nephropathy","volume":"36","author":"Moriyama","year":"2014","journal-title":"Ren Fail"},{"key":"10.1124\/pharmrev.123.000815_bib170","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008250","article-title":"Race\/Ethnic and Sex Differences in the Association of Atherosclerotic Cardiovascular Disease Risk and Healthy Lifestyle Behaviors","volume":"7","author":"Morris","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1124\/pharmrev.123.000815_bib171","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J Am Chem Soc"},{"key":"10.1124\/pharmrev.123.000815_bib172","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3389\/fmicb.2018.00750","article-title":"Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds","volume":"9","author":"Nan","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1124\/pharmrev.123.000815_bib173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","article-title":"Gene therapy for hemophilia","volume":"2019","author":"Nathwani","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1124\/pharmrev.123.000815_bib174","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/CIRCRESAHA.120.315890","article-title":"The Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk","volume":"128","author":"Nayor","year":"2021","journal-title":"Circ Res"},{"key":"10.1124\/pharmrev.123.000815_bib175","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2011.12.028","article-title":"Diagnosis and management of patients with \u03b11-antitrypsin (A1AT) deficiency","volume":"10","author":"Nelson","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/pharmrev.123.000815_bib176","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib177","doi-asserted-by":"crossref","first-page":"7969","DOI":"10.1038\/ncomms8969","article-title":"DNA\/RNA heteroduplex oligonucleotide for highly efficient gene silencing","volume":"6","author":"Nishina","year":"2015","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.123.000815_bib178","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.18379","article-title":"Current and future therapies for haemophilia-Beyond factor replacement therapies","volume":"200","author":"Nogami","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1124\/pharmrev.123.000815_bib179","doi-asserted-by":"crossref","first-page":"665","DOI":"10.5551\/jat.RV17050","article-title":"Homozygous Familial Hypercholesterolemia","volume":"28","author":"Nohara","year":"2021","journal-title":"J Atheroscler Thromb"},{"key":"10.1124\/pharmrev.123.000815_bib180","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","article-title":"Overview of complement activation and regulation","volume":"33","author":"Noris","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1124\/pharmrev.123.000815_bib181","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3390\/molecules23061302","article-title":"A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey","volume":"23","author":"Oberemok","year":"2018","journal-title":"Molecules"},{"key":"10.1124\/pharmrev.123.000815_bib182","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"O\u2019Donoghue","year":"2022","journal-title":"Am Heart J"},{"key":"10.1124\/pharmrev.123.000815_bib183","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib184","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nature14138","article-title":"Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9","volume":"520","author":"Ohto","year":"2015","journal-title":"Nature"},{"key":"10.1124\/pharmrev.123.000815_bib185","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab Prophylaxis in Hemophilia A with Inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117605","article-title":"Neurology of the acute hepatic porphyrias","volume":"428","author":"Oliveira Santos","year":"2021","journal-title":"J Neurol Sci"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.123.000815_bib187","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11789-017-0084-1","article-title":"Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies","volume":"12","author":"Ors\u00f3","year":"2017","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1124\/pharmrev.123.000815_bib188","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002184","article-title":"Lipid lowering with inclisiran: a real-world single-centre experience","volume":"9","author":"Padam","year":"2022","journal-title":"Open Heart"},{"key":"10.1124\/pharmrev.123.000815_bib189","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12272-019-01116-1","article-title":"Current pharmacotherapies for atherosclerotic cardiovascular diseases","volume":"42","author":"Park","year":"2019","journal-title":"Arch Pharm Res"},{"key":"10.1124\/pharmrev.123.000815_bib190","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort","volume":"19","author":"Pasi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1124\/pharmrev.123.000815_bib191","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib192","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1517\/14656566.2010.512006","article-title":"Mipomersen as a potential adjunctive therapy for hypercholesterolemia","volume":"11","author":"Patel","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/pharmrev.123.000815_bib193","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1073\/pnas.74.10.4370","article-title":"Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation","volume":"74","author":"Paterson","year":"1977","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.123.000815_bib194","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0033-1354426","article-title":"Defining severity of hemophilia: more than factor levels","volume":"39","author":"Pavlova","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1124\/pharmrev.123.000815_bib195","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1089\/nat.2017.0668","article-title":"The Distinct and Cooperative Roles of Toll-Like Receptor 9 and Receptor for Advanced Glycation End Products in Modulating In Vivo Inflammatory Responses to Select CpG and Non-CpG Oligonucleotides","volume":"27","author":"Paz","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/pharmrev.123.000815_bib196","first-page":"669","article-title":"Familial hypercholesterolemia","volume":"14","author":"Pejic","year":"2014","journal-title":"Ochsner J"},{"key":"10.1124\/pharmrev.123.000815_bib197","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-136501","article-title":"Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study","volume":"136","author":"Pipe","year":"2020","journal-title":"Blood"},{"key":"10.1124\/pharmrev.123.000815_bib198","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1089\/nat.2019.0797","article-title":"Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2'- O-Methoxyethyl Antisense Oligonucleotide","volume":"29","author":"Pirie","year":"2019","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/pharmrev.123.000815_bib199","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/FJC.0000000000001045","article-title":"The Role of Antisense Therapies Targeting Lipoprotein(a)","volume":"78","author":"Plakogiannis","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pharmrev.123.000815_bib200","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00415-014-7373-0","article-title":"Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy","volume":"261","author":"Plante-Bordeneuve","year":"2014","journal-title":"J Neurol"},{"key":"10.1124\/pharmrev.123.000815_bib201","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib202","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.123.000815_bib203","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"10.1124\/pharmrev.123.000815_bib204","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.3390\/nu13124562","article-title":"Methylenetetrahydrofolate (MTHFR), the One-Carbon Cycle, and Cardiovascular Risks","volume":"13","author":"Raghubeer","year":"2021","journal-title":"Nutrients"},{"key":"10.1124\/pharmrev.123.000815_bib205","first-page":"17.20.1","article-title":"Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias","volume":"86","author":"Ramanujam","year":"2015","journal-title":"Curr Protoc Hum Genet"},{"key":"10.1124\/pharmrev.123.000815_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115052","article-title":"A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics","volume":"201","author":"Ranjbar","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/pharmrev.123.000815_bib207","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.118.034710","article-title":"Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1","volume":"138","author":"Ray","year":"2018","journal-title":"Circulation"},{"key":"10.1124\/pharmrev.123.000815_bib208","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1124\/pharmrev.123.000815_bib209","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib210","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.coph.2021.06.001","article-title":"Alpha1-antitrypsin deficiency: New therapies on the horizon","volume":"59","author":"Remih","year":"2021","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/pharmrev.123.000815_bib211","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pharmrev.123.000815_bib212","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.123.000815_bib214","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.123.000815_bib215","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2215\/CJN.07420716","article-title":"IgA Nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.123.000815_bib216","first-page":"14","article-title":"Fomivirsen approved for CMV retinitis","volume":"4","author":"Roehr","year":"1998","journal-title":"J Int Assoc Physicians AIDS Care"},{"key":"10.1124\/pharmrev.123.000815_bib217","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1124\/pharmrev.123.000815_bib218","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4103\/0974-2700.82225","article-title":"Revisiting hemophilia management in acute medicine","volume":"4","author":"Sahu","year":"2011","journal-title":"J Emerg Trauma Shock"},{"key":"10.1124\/pharmrev.123.000815_bib219","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0033-1353996","article-title":"Hemophilia a and hemophilia B: different types of diseases?","volume":"39","author":"Santagostino","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1124\/pharmrev.123.000815_bib220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12703\/b\/9-1","article-title":"Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management","volume":"9","author":"Santos","year":"2020","journal-title":"Fac Rev"},{"key":"10.1124\/pharmrev.123.000815_bib221","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","article-title":"Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension","volume":"36","author":"Santos","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1124\/pharmrev.123.000815_bib222","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pharmrev.123.000815_bib223","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa1807838","article-title":"Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria","volume":"380","author":"Sardh","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib224","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","article-title":"Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children","volume":"24","author":"Sas","year":"2022","journal-title":"Genet Med"},{"key":"10.1124\/pharmrev.123.000815_bib225","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1124\/pharmrev.123.000815_bib226","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/ajt.17009","article-title":"Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation","volume":"22","author":"Schmidt","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1124\/pharmrev.123.000815_bib227","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: First Approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.123.000815_bib228","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: First Approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.123.000815_bib229","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.123.000815_bib230","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/TACG.S257511","article-title":"Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated Overview of SERPINA1 Variation Spectrum","volume":"14","author":"Seixas","year":"2021","journal-title":"Appl Clin Genet"},{"key":"10.1124\/pharmrev.123.000815_bib231","series-title":"GeneReviews","article-title":"Hereditary Transthyretin Amyloidosis","author":"Sekijima","year":"1993"},{"key":"10.1124\/pharmrev.123.000815_bib232","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1124\/jpet.105.084004","article-title":"Non-CpG-containing antisense 2\u2032-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88","volume":"314","author":"Senn","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.123.000815_bib233","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.123.000815_bib234","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187574","article-title":"Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia","volume":"12","author":"Sewing","year":"2017","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.123.000815_bib235","series-title":"Hyperoxaluria","author":"Shah","year":"2023"},{"key":"10.1124\/pharmrev.123.000815_bib236","first-page":"53","article-title":"Recent advances in the pharmacotherapy of TTR amyloidosis of the heart","volume":"5","author":"Shah","year":"2021","journal-title":"Vessel Plus"},{"key":"10.1124\/pharmrev.123.000815_bib237","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1369\/0022155413503662","article-title":"Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma","volume":"61","author":"Shi","year":"2013","journal-title":"J Histochem Cytochem"},{"key":"10.1124\/pharmrev.123.000815_bib238","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.3748\/wjg.14.4111","article-title":"Liver in systemic disease","volume":"14","author":"Shimizu","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1124\/pharmrev.123.000815_bib239","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jpeds.2013.03.077","article-title":"Disorders of protein misfolding: alpha-1-antitrypsin deficiency as prototype","volume":"163","author":"Silverman","year":"2013","journal-title":"J Pediatr"},{"key":"10.1124\/pharmrev.123.000815_bib240","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1053\/j.ajkd.2021.05.016","article-title":"Primary Hyperoxaluria Type 3 Can Also Result in Kidney Failure: A Case Report","volume":"79","author":"Singh","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/pharmrev.123.000815_bib241","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11886-011-0219-9","article-title":"Familial hypercholesterolemia: present and future management","volume":"13","author":"Sjouke","year":"2011","journal-title":"Curr Cardiol Rep"},{"key":"10.1124\/pharmrev.123.000815_bib242","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.clinthera.2022.07.008","article-title":"Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study","volume":"44","author":"Sohn","year":"2022","journal-title":"Clin Ther"},{"key":"10.1124\/pharmrev.123.000815_bib243","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17980-9","article-title":"Clinical and molecular characterization of primary hyperoxaluria in Egypt","volume":"12","author":"Soliman","year":"2022","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.123.000815_bib244","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1124\/pharmrev.123.000815_bib245","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3390\/ph15121573","article-title":"Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy","volume":"15","author":"Sosnowska","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1124\/pharmrev.123.000815_bib246","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13998","article-title":"Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres","volume":"26","author":"Soucie","year":"2020","journal-title":"Haemophilia"},{"key":"10.1124\/pharmrev.123.000815_bib247","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/pharmrev.123.000815_bib249","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1124\/pharmrev.123.000815_bib250","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"key":"10.1124\/pharmrev.123.000815_bib251","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/eurheartj\/ehaa171","article-title":"Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)","volume":"41","author":"Stiekema","year":"2020","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.123.000815_bib252","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3109\/15412555.2013.763782","article-title":"The challenge of detecting alpha-1 antitrypsin deficiency","volume":"10","author":"Stoller","year":"2013","journal-title":"COPD"},{"key":"10.1124\/pharmrev.123.000815_bib253","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268421","article-title":"The epidemiology and evolution of IgA nephropathy over two decades: A single centre experience","volume":"17","author":"Storrar","year":"2022","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.123.000815_bib254","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2205416","article-title":"Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency","volume":"387","author":"Strnad","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib255","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1124\/pharmrev.123.000815_bib256","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/nat.2019.0796","article-title":"Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis","volume":"30","author":"Sutherland","year":"2020","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/pharmrev.123.000815_bib257","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-021-01511-3","article-title":"Givosiran: A Review in Acute Hepatic Porphyria","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.123.000815_bib258","doi-asserted-by":"crossref","first-page":"583","DOI":"10.5551\/jat.RV17034","article-title":"Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease","volume":"26","author":"Tada","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"10.1124\/pharmrev.123.000815_bib259","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0092-8674(93)90250-T","article-title":"Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria","volume":"73","author":"Takeda","year":"1993","journal-title":"Cell"},{"key":"10.1124\/pharmrev.123.000815_bib260","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000030323","article-title":"Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria","volume":"61","author":"Takei","year":"1998","journal-title":"Urol Int"},{"key":"10.1124\/pharmrev.123.000815_bib261","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00467-020-04774-2","article-title":"The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab","volume":"36","author":"Tanaka","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1124\/pharmrev.123.000815_bib262","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1023\/A:1005326510239","article-title":"Primary hyperoxaluria type 1: diagnostic relevance of mutations and polymorphisms in the alanine:glyoxylate aminotransferase gene (AGXT)","volume":"20","author":"Tarn","year":"1997","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.123.000815_bib263","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/15412555.2013.765839","article-title":"Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy","volume":"10","author":"Teckman","year":"2013","journal-title":"COPD"},{"key":"10.1124\/pharmrev.123.000815_bib264","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/17474124.2014.943187","article-title":"Alpha-1 antitrypsin and liver disease: mechanisms of injury and novel interventions","volume":"9","author":"Teckman","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1124\/pharmrev.123.000815_bib265","first-page":"3","article-title":"The spectrum of clinical sequelae associated with alpha-1 antitrypsin deficiency","volume":"12","author":"Tejwani","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1124\/pharmrev.123.000815_bib266","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1006304","article-title":"A perspective on oligonucleotide therapy: Approaches to patient customization","volume":"13","author":"Thakur","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.123.000815_bib267","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pharmrev.123.000815_bib268","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/hep.30508","article-title":"The Role of Complement in Liver Injury, Regeneration, and Transplantation","volume":"70","author":"Thorgersen","year":"2019","journal-title":"Hepatology"},{"key":"10.1124\/pharmrev.123.000815_bib269","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.840797","article-title":"Familial Hypercholesterolemia Prevalence Among Ethnicities-Systematic Review and Meta-Analysis","volume":"13","author":"Toft-Nielsen","year":"2022","journal-title":"Front Genet"},{"key":"10.1124\/pharmrev.123.000815_bib270","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/jpet.122.001234","article-title":"RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies","volume":"384","author":"Traber","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.123.000815_bib271","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00439-016-1647-9","article-title":"Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk","volume":"135","author":"Tragante","year":"2016","journal-title":"Hum Genet"},{"key":"10.1124\/pharmrev.123.000815_bib272","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) Reduction in Persons with Cardiovascular Disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.123.000815_bib273","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jhep.2018.03.012","article-title":"Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients","volume":"69","author":"Turner","year":"2018","journal-title":"J Hepatol"},{"issue":"Suppl 3","key":"10.1124\/pharmrev.123.000815_bib274","first-page":"S147","article-title":"Hemophilia A: Dental considerations and management","volume":"4","author":"Shastry","year":"2014","journal-title":"J Int Soc Prev Community Dent"},{"key":"10.1124\/pharmrev.123.000815_bib275","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A Review of Patisiran (ONPATTRO\u00ae) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1124\/pharmrev.123.000815_bib276","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/01.hjh.0000163156.37363.47","article-title":"Thiazide diuretics enhance nocturnal blood pressure fall and reduce proteinuria in immunoglobulin A nephropathy treated with angiotensin II modulators","volume":"23","author":"Uzu","year":"2005","journal-title":"J Hypertens"},{"key":"10.1124\/pharmrev.123.000815_bib277","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ndt\/18.2.273","article-title":"Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome","volume":"18","author":"van Woerden","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/pharmrev.123.000815_bib278","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bbagrm.2008.07.005","article-title":"RISC-target interaction: Cleavage and translational suppression","volume":"1779","author":"Van den berg","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/pharmrev.123.000815_bib279","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/liv.15090","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study","volume":"42","author":"Ventura","year":"2022","journal-title":"Liver Int"},{"key":"10.1124\/pharmrev.123.000815_bib280","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s11255-010-9824-6","article-title":"Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion?","volume":"43","author":"Vigen","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"10.1124\/pharmrev.123.000815_bib281","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1124\/pharmrev.123.000815_bib282","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1124\/pharmrev.123.000815_bib283","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/tgh-2020-01","article-title":"The acute hepatic porphyrias","volume":"6","author":"Wang","year":"2021","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1124\/pharmrev.123.000815_bib284","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s13023-022-02463-x","article-title":"Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study","volume":"17","author":"Wang","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1124\/pharmrev.123.000815_bib285","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.7150\/thno.55795","article-title":"Organ-organ communication: The liver\u2019s perspective","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1124\/pharmrev.123.000815_bib286","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/d41573-020-00078-0","article-title":"RNA therapeutics on the rise","volume":"19","author":"Wang","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.123.000815_bib287","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/JBM.S133616","article-title":"Identification of patients with congenital hemophilia in a large electronic health record database","volume":"8","author":"Wang","year":"2017","journal-title":"J Blood Med"},{"key":"10.1124\/pharmrev.123.000815_bib288","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/FJC.0000000000001053","article-title":"Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins","volume":"78","author":"Warden","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pharmrev.123.000815_bib289","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1358\/dof.2022.47.1.3369190","article-title":"Antisense oligonucleotide targeting apolipoprotein(a) Treatment of lipoprotein disorders Treatment of cardiovascular diseases","volume":"47","author":"Warden","year":"2022","journal-title":"Drugs Future"},{"key":"10.1124\/pharmrev.123.000815_bib290","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.antiviral.2012.02.004","article-title":"Advanced morpholino oligomers: a novel approach to antiviral therapy","volume":"94","author":"Warren","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1124\/pharmrev.123.000815_bib291","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J Pathol"},{"key":"10.1124\/pharmrev.123.000815_bib292","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1086\/302586","article-title":"Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation","volume":"65","author":"Whatley","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1124\/pharmrev.123.000815_bib293","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.08000520","article-title":"Pathophysiology and Treatment of Enteric Hyperoxaluria","volume":"16","author":"Witting","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.123.000815_bib294","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00281-017-0663-8","article-title":"Diseases of complement dysregulation-an overview","volume":"40","author":"Wong","year":"2018","journal-title":"Semin Immunopathol"},{"key":"10.1124\/pharmrev.123.000815_bib295","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135348","article-title":"Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease","volume":"5","author":"Wooddell","year":"2020","journal-title":"JCI Insight"},{"key":"10.1124\/pharmrev.123.000815_bib296","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1124\/pharmrev.123.000815_bib297","article-title":"Nephrotoxicity of marketed antisense oligonucleotide drugs","volume":"32","author":"Wu","year":"2022","journal-title":"Curr Opin Toxicol"},{"key":"10.1124\/pharmrev.123.000815_bib298","series-title":"Comprehensive Biotechnology","first-page":"560","article-title":"RNA Interference Technology","author":"Xu","year":"2019"},{"key":"10.1124\/pharmrev.123.000815_bib299","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/CLEP.S245642","article-title":"Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review","volume":"12","author":"Yan","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1124\/pharmrev.123.000815_bib300","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40120-021-00268-x","article-title":"Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR","volume":"10","author":"Yarlas","year":"2021","journal-title":"Neurol Ther"},{"key":"10.1124\/pharmrev.123.000815_bib301","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40291-021-00573-z","article-title":"Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension","volume":"26","author":"Yasuhara","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"10.1124\/pharmrev.123.000815_bib302","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/pharmrev.123.000815_bib303","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1093\/nar\/gkh516","article-title":"2\u2032-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro","volume":"32","author":"Yoo","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/pharmrev.123.000815_bib304","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.123.000815_bib305","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/pr.120.019554","article-title":"RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges","volume":"72","author":"Yu","year":"2020","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.123.000815_bib306","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107967","article-title":"Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination","volume":"230","author":"Yu","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pharmrev.123.000815_bib307","first-page":"65","article-title":"Lung and liver transplantation in patients with alpha-1 antitrypsin deficiency","volume":"12","author":"Zamora","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1124\/pharmrev.123.000815_bib308","first-page":"378","article-title":"Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years","volume":"17","author":"Zanon","year":"2019","journal-title":"Blood Transfus"},{"key":"10.1124\/pharmrev.123.000815_bib309","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: Updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pharmrev.123.000815_bib310","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcph.1480","article-title":"Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pharmrev.123.000815_bib311","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.1553","article-title":"Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pharmrev.123.000815_bib312","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.3390\/ijms23052736","article-title":"Current Advances in RNA Therapeutics for Human Diseases","volume":"23","author":"Zogg","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724006094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724006094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pharmrev.123.000815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T04:12:38Z","timestamp":1739851958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724006094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":308,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0031699724006094"],"URL":"https:\/\/doi.org\/10.1124\/pharmrev.123.000815","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pharmrev.123.000815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}